Medicare spending on set of diabetes drugs skyrocketed — report
The use of a subset of common diabetes drugs skyrocketed in the US Medicare program over a five-year period ending in 2023, according to a new report from the HHS inspector general. The
View ArticleFDA meeting to pick next winter's flu shot is canceled
A meeting by a panel of science advisors to choose flu strains to include in a vaccine for next fall has been canceled on short notice, according to a member of the committee, raising concerns ...
View ArticleSorriso Pharmaceuticals outlines Phase 1b ulcerative colitis data for oral...
Private startup Sorriso Pharmaceuticals laid out Phase 1b data at a medical conference last weekend as part of its effort to bring an oral antibody to market for IBD patients. The results come after...
View ArticleKallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial
Kallyope, a New York City biotech that has raised about $480 million over the past decade, quietly released results of its Phase 2 study in obesity in ...
View ArticleMerck mulls new site in Delaware; Granules India buys peptide CDMO
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Merck has received a $30 million strategic fund from the state of...
View ArticleBayer CEO Bill Anderson previews 2025 turnaround plans
Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native felt like he was stuck in the same loop year after year. The company ...
View ArticleHansoh ends collaboration with Silence; Vir hunts for HBV drug partner
Plus, news about Alopexx, Medigene, EpimAb and Belite Bio: Hansoh backs out of siRNA pact with Silence Therapeutics: The London-based biotech said Hansoh has decided not to ...
View ArticleTeladoc reports $1B net loss as it works to turn around its business
Teladoc wrapped up its financial year with a $1 billion net loss and disappointing results as the telehealth giant continues to work on its turnaround strategy. The net loss was in a big part due ...
View ArticleVerve is latest gene editing company to suffer setback, as Vertex walks away...
Verve Therapeutics has not escaped the doom that seems to be engulfing the gene editing sector of late. The company said Thursday that Vertex Pharmaceuticals handed back the rights to a ...
View ArticleOpenAI meets cancer care
Most healthcare organizations have been using AI for decidedly unglamorous tasks like documentation and billing. Now we’re starting to see how it could be used in clinical care. Color Health and OpenAI...
View ArticleDrug policy veteran at CMS to depart on Friday
John Coster, CMS' senior technical advisor for the Medicare drug rebate and negotiation group, told Endpoints News that he's leaving his agency on Friday. Coster, who has been at CMS for more than a...
View ArticlePharma-backed Mission Therapeutics stops preclinical operations, focuses on...
Clinical-stage biotech Mission Therapeutics is closing its preclinical laboratory operations in Cambridge, UK, a spokesperson confirmed to Endpoints News. The biotech will focus on its clinical...
View ArticleHHS’ vaccine injury panel in limbo after monthlong meeting delay
More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal compensation program for vaccine injuries has no information on when its operations...
View ArticleCDC investigating hospitalizations after chikungunya vaccination
The CDC is looking into a handful of hospitalization cases after people got Ixchiq, Valneva’s vaccine for chikungunya, according to a notice posted to the CDC’s webpage. The notice, posted Tuesday ...
View ArticleLilly joins molecular glue field with Magnet deal worth up to $1.25B
Another day, another molecular glue deal in the biopharma world. This time around, it’s Eli Lilly partnering with the private startup Magnet Biomedicine on the technology. Lilly will pay up to $40...
View ArticlePfizer vet William Pao’s next venture; Sanofi’s computational science exec...
William Pao, a longtime R&D leader at Roche who briefly held the chief development officer post at Pfizer until the summer of 2023, has been stealthily leading a biotech ...
View ArticleTrump’s science crackdown hits rare disease research: ‘We need to sit down...
Jill Wood had pinned her hopes on a little-known federal program to fund her son’s gene therapy. The initiative, which awards vouchers to companies targeting rare pediatric diseases, offered her son a...
View ArticleBridgeBio oncology spinout to go public via combination with SPAC from...
The second blank-check vehicle from Cormorant's Bihua Chen plans to take BridgeBio's oncology spinout onto the Nasdaq. The special purpose acquisition company — known as Helix Acquisition Corp. II —...
View ArticlePacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics
Plus, news about Recursion, Nxera, Viatris and DualityBio: Pacira BioSciences takes on GQ Bio: The non-opioid pain biotech is spending $32 million to buy the remaining ...
View ArticlePraxis' essential tremor drug fails interim Phase 3 readout
Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price {$PRAX} down roughly 40%. The company was studying whether an experimental drug...
View Article